Paolo Marchetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Gynecological and reproductive factors and the risk of pancreatic cancer. a case-control study	PANCREATOLOGY	2020
Evaluation of prognostic factors for survival in transverse colon cancer	CANCERS	2020
Risk of coronavirus disease 2019 in patients treated for cancer. An immune response–based hypothesis	EUROPEAN JOURNAL OF CANCER	2020
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients	JOURNAL OF PERSONALIZED MEDICINE	2020
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137 + T-cells	EBIOMEDICINE	2020
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study	CANCERS	2020
No evidence of sars-cov-2 circulation in rome (Italy) during the pre-pandemic period: Results of a retrospective surveillance	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH	2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	CLINICAL LUNG CANCER	2020
Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2020
Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2	FRONTIERS IN CHEMISTRY	2020
Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations	RARE TUMORS	2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes	CLINICAL & TRANSLATIONAL ONCOLOGY.	2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events	EUROPEAN JOURNAL OF CANCER	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer	LUNG CANCER MANAGEMENT	2020
The perception of the information received from the doctor. A study on 103 onco-hematological patients with metastatic disease	ADVANCES IN SOCIAL SCIENCES RESEARCH JOURNAL	2020
https://researchopenworld.com/covid-19-and-oncological-health-workers-psychological-reactions-and-interventions/#	Cancer Studies and Therapeutics	2020